Compounds and uses thereof for the modulation of hemoglobin

Patent metadata

Field	Value
Publication number	US-11053195-B2
Application number	US-201816186275-A
Country	US
Kind code	B2
Filing date	Nov 9, 2018
Priority date	Mar 15, 2013
Publication date	Jul 6, 2021
Grant date	Jul 6, 2021

Abstract

Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

First claim

The invention claimed is:

1. A compound of Formula (I):

or a pharmaceutically acceptable salt thereof,
wherein:
R 3 is —NR 1 R 2 ;
R 1 and R 2 , together with the nitrogen atom they are attached to, form a 4-7 membered heterocycle optionally substituted with 1-3 C1-C6 alkyl;
ring B is phenyl, 5-6 membered monocyclic heteroaryl having 1-3 nitrogen atoms or oxidized forms of N, or 4-6 membered monocyclic heterocycle containing up to 5 ring heteroatoms, wherein the heteroatom is selected from the group consisting of O, N, S and oxidized forms of N and S, and wherein the phenyl, 5-6 membered monocyclic heteroaryl, and 4-6 membered monocyclic heterocycle are each optionally substituted with 1-3 substituents independently selected from C1-C4 alkyl, COR 15 , and COOR 15 ;
each R 15 is independently C 1 -C 4 alkyl; and
R 4 is OH, halo, C 1 -C 6 alkoxy optionally substituted with 1-5 halo, or C 3 -C 6 cycloalkoxy.

2. The compound of claim 1 , wherein ring B is 5-6 membered monocyclic heteroaryl optionally substituted with 1-3 substituents independently selected from C 1 -C 4 alkyl, COR 15 , and COOR 15 .

3. The compound of claim 1 , wherein ring B is 4-6 membered monocyclic heterocycle optionally substituted with 1-3 substituents independently selected from C 1 -C 4 alkyl, COR 15 , and COOR 15 .

4. The compound of claim 1 , wherein R 4 is OH.

5. The compound of claim 1 , wherein R 1 and R 2 together with the nitrogen atom they are attached to form a 4-7 membered heterocycle.

6. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

7. A method for treating sickle cell disease comprising administering to a subject in need thereof a compound of claim 1 .

8. A method for treating sickle cell disease comprising administering to a subject in need thereof a pharmaceutical composition of claim 6 .

9. A method for preparing a compound of formula (A):

comprising contacting a compound of formula:

with an acid under conditions sufficient to form a compound of formula (A).

10. The method of claim 9 , further comprising contacting a compound of formula (C):

with methyl lithium and diisopropylamine under conditions sufficient to form a compound of formula (B).

11. The method of claim 10 , further comprising contacting a compound of formula (D):

with 1-bromo-2-methoxyethane and a base under conditions sufficient to form a compound of formula (C).

Assignees

• Global Blood Therapeutics Inc

Inventors

• Xu Qing
• Li Zhe
• Gwaltney Ii Stephen L

Classifications

• C07D207/08 Primary

  with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms · CPC title

• A61K31/445

  Non condensed piperidines, e.g. piperocaine · CPC title

• A61K31/4025

  not condensed and containing further heterocyclic rings, e.g. cromakalim · CPC title

• C07D403/06

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title

• C07D401/06

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title